/PRNewswire/ OnQuality Pharmaceuticals ("OnQuality"), an oncology company developing targeted supportive therapies to address unmet needs in oncodermatology.
To help celebrate GEN’s 40th Anniversary with this special October issue, we asked scientists and business professionals in academia and industry to give us their reflections, impressions, and insights on the biotechnology industry and the life sciences.
Share this article
Share this article
SEATTLE, May 19, 2021 /PRNewswire/ OnQuality Pharmaceuticals ( OnQuality ), a targeted cancer supportive care company developing medications to address specific side effects and improve the quality of life for patients receiving anti-cancer medications, today announced that abstracts for the NOVA-II clinical trial evaluating OnQuality s lead candidate, OQL011, have been selected for presentations at two upcoming meetings: a Trial in Progress poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held virtually from June 4-8, 2021, and an oral presentation at the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) Annual Meeting, being held virtually from June 24-26, 2021. The abstracts for both presentations include an update on the ongoing Phase II clinical trial and are both titled A Study to Investigate OQL011 on VEGFR Inhibitor-Associated
OnQuality Pharmaceuticals to Present on NOVA-II Trial Evaluating OQL011 at the 2021 ASCO and MASCC/ISOO Annual Meetings prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
05/13/2021
Mark A. Reed, the Harold Hodgkinson Professor of Electrical Engineering & Applied Physics, and integral member of the SEAS community for three decades, passed away peacefully in his home on May 5, 2021, at the age of 66.
Reed was an exemplary engineer and physicist, an intellectual pioneer, and internationally recognized for his pioneering innovations in nanotechnology. He joined the Yale faculty in 1990 after working at Texas Instruments, where he coined the term quantum dots and demonstrated the first quantum dot device. For more than 30 years at Yale, Reed was extremely active and continued his streak of firsts, including the first conductance measurement of a single molecule, the first single molecule transistor, and the development of CMOS nanowire biosensors. Reed was the author of more than 200 professional publications, 6 books, delivered 75 plenary and over 400 invited talks, and holds 33 U.S. and foreign patents on quantum effect, heterojunction, and molecu